Mixed lineage kinase domain-like protein
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric(1) Consistent with protein copy count | Chain A; UniProt 191–471 | Fragment:UNP residues 191-471 | 6UX 1-[4-[methyl-[2-[(3-sulfamoylphenyl)amino]pyrimidin-4-yl]amino]phenyl]-3-[4-(trifluoromethyloxy)phenyl]urea × 1 | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION, SITTING DROP;pH 7;291 K;0.1M Na Citrate and 15% PEG3350 | Resolution 2.88 Å R-free 0.256 |
| 2 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric(1) Consistent with protein copy count | Chain B; UniProt 191–471 | Fragment:UNP residues 191-471 | 6UX 1-[4-[methyl-[2-[(3-sulfamoylphenyl)amino]pyrimidin-4-yl]amino]phenyl]-3-[4-(trifluoromethyloxy)phenyl]urea × 1 | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION, SITTING DROP;pH 7;291 K;0.1M Na Citrate and 15% PEG3350 | Resolution 2.88 Å R-free 0.256 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 5KNJ | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 2MSV Solution structure of the MLKL N-terminal domain Deposited 2014-08-07 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
1–154(154 aa)
Fragment:N-terminal domain, residues 1-154
|
Mutation:M1L | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 0.12;Pressure ambient
NMR sample composition
1.5 mM [U-99% 13C; U-99% 15N] protein, 20 mM HEPES, 100 mM sodium chloride, 2 mM TCEP, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition
1.5 mM [U-99% 15N] protein, 20 mM HEPES, 100 mM sodium chloride, 2 mM TCEP, 100% D2O | 100% D2O
|
Resolution not provided |
| 4M67 Crystal structure of the human MLKL kinase-like domain Deposited 2013-08-09 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
179–471(293 aa)
Fragment:UNP residues 179-471
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;291 K;0.1M MES, 13% PEG 6000, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.90 Å R-free 0.225 |
| 4MWI Crystal structure of the human MLKL pseudokinase domain Deposited 2013-09-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
183–471(289 aa)
Fragment:unp residues 183-471
|
Not recorded | PXN (2S)-1-[3-{[(2R)-2-hydroxypropyl]oxy}-2,2-bis({[(2R)-2-hydroxypropyl]oxy}methyl)propoxy]propan-2-ol × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;25% w/v pentaerythitol propoxylate, 0.1M Tris chloride, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.70 Å R-free 0.194 |
| 5KO1 Pseudokinase Domain of MLKL bound to Compound 4. Deposited 2016-06-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
191–471(281 aa)
Fragment:UNP residues 191-471
|
Not recorded | 6UY [(1~{R})-2-[(4-fluorophenyl)amino]-2-oxidanylidene-1-phenyl-ethyl] 3-azanylpyrazine-2-carboxylate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;0.1M BisTRIS pH 6.5 20% PEG3350
|
Resolution 2.16 Å R-free 0.226 |
| 6BWK Crystal structure of the human MLKL pseudokinase domain T357E/S358E mutant Deposited 2017-12-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
190–471(282 aa)
Fragment:UNP Residues 190-471
|
Mutation:T357E S358E | GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;5% w/v polyethylene glycol 8000, 20% v/v polyethylene glycol 300, 0.1M Tris chloride pH 8.5, 10% v/v glycerol
|
Resolution 2.79 Å R-free 0.297 |
| 6D74 Direct Activation of the Executioner Domain of MLKL by a Select Repertoire of Inositol Phosphates Deposited 2018-04-24 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
1–156(156 aa)
Fragment:residues 1-156
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.8;303 K;Ionic strength (raw mmCIF value) 0;Pressure 1
NMR sample composition
500 uM [U-13C; U-15N] protein, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 6LK5 MLKL mutant - T357ES358D Deposited 2019-12-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
1–471(471 aa)
|
Mutation:T357E, S358D | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;5%(v/v) 2-Methyl-2,4-pentanediol,
0.1M HEPES(pH7.5),
10%(w/v) PEG 10000
|
Resolution 2.50 Å R-free 0.238 |
| 6LK6 MLKL mutant - T357AS358A Deposited 2019-12-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
179–471(293 aa)
|
Mutation:T357A, S358A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;14%(w/v) PEG 6000,
5% EG,
0.1M HEPES(pH7.5)
|
Resolution 2.41 Å R-free 0.247 |
| 6O5Z Crystal Structure of the human MLKL pseudokinase domain bound to compound 2 Deposited 2019-03-04 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
190–471(282 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.88;293 K;0.18 M magnesium chloride, 26.8% (w/v) PEG 3350, 0.1 M sodium HEPES pH 7.88
|
Resolution 2.29 Å R-free 0.232 |
| 6O5Z Crystal Structure of the human MLKL pseudokinase domain bound to compound 2 Deposited 2019-03-04 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
190–471(282 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 LN4 1-[2-fluoranyl-5-(trifluoromethyl)phenyl]-3-[4-[methyl-[2-[(3-sulfamoylphenyl)amino]pyrimidin-4-yl]amino]phenyl]urea × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.88;293 K;0.18 M magnesium chloride, 26.8% (w/v) PEG 3350, 0.1 M sodium HEPES pH 7.88
|
Resolution 2.29 Å R-free 0.232 |
| 6UX8 Structure of monobody 33 MLKL N-terminal domain complex Deposited 2019-11-07 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
5–154(150 aa)
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;25% PEG-MME 550, 0.1 M MES pH 6.5, 0.01 M Zinc acetate
|
Resolution 2.50 Å R-free 0.296 |
| 6ZLE Solution structure of unliganded MLKL executioner domain Deposited 2020-06-30 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
2–154(153 aa)
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.5;298 K;Ionic strength (raw mmCIF value) 20 mM sodium phosphate,150 mM sodium chloride;Pressure 1
NMR measurement conditions
pH 7.1;298 K;Ionic strength (raw mmCIF value) 20 mM sodium phosphate,150 mM sodium chloride;Pressure 1
NMR sample composition
400 uM [U-13C; U-15N] MLKL, 93% H2O/7% D2O | 93% H2O/7% D2O
NMR sample composition
430 uM [U-13C; U-15N] MLKL, 100% D2O | 100% D2O
|
Resolution not provided |
| 6ZPR Solution structure of MLKL executioner domain in complex with a covalent inhibitor Deposited 2020-07-09 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
2–85(84 aa)
Chain A
86–154(69 aa)
|
Not recorded | QOK 7-(2-methoxyethoxymethyl)-1,3-dimethyl-purine-2,6-dione × 1 |
SOLUTION NMR
NMR measurement conditions
pH 7.5;298 K;Ionic strength (raw mmCIF value) 20 mM sodium phosphate, 150 mM sodium chloride;Pressure 1
NMR measurement conditions
pH 7.1;298 K;Ionic strength (raw mmCIF value) 20 mM sodium phosphate, 150 mM sodium chloride;Pressure 1
NMR sample composition
340 uM [U-13C; U-15N] MLKL, 1200 uM Compound, 93% H2O/7% D2O | 93% H2O/7% D2O
NMR sample composition
385 uM [U-13C; U-15N] MLKL, 840 uM Compound, 100% D2O | 100% D2O
|
Resolution not provided |
| 6ZVO Crystal structure of unliganded MLKL executioner domain Deposited 2020-07-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
2–150(149 aa)
|
Not recorded | CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;31 % Polyethylene glycol monomethyl ether 2,000, 0.15 M Potassium bromide, 0.1 M TRIS, pH 9
|
Resolution 1.37 Å R-free 0.234 |
| 6ZVO Crystal structure of unliganded MLKL executioner domain Deposited 2020-07-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
2–150(149 aa)
|
Not recorded | CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;31 % Polyethylene glycol monomethyl ether 2,000, 0.15 M Potassium bromide, 0.1 M TRIS, pH 9
|
Resolution 1.37 Å R-free 0.234 |
| 6ZVO Crystal structure of unliganded MLKL executioner domain Deposited 2020-07-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain C
2–150(149 aa)
|
Not recorded | CL CHLORIDE ION × 1 BR BROMIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;31 % Polyethylene glycol monomethyl ether 2,000, 0.15 M Potassium bromide, 0.1 M TRIS, pH 9
|
Resolution 1.37 Å R-free 0.234 |
| 6ZZ1 Crystal structure of MLKL executioner domain in complex with a covalent inhibitor Deposited 2020-08-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
2–150(149 aa)
|
Not recorded | QOK 7-(2-methoxyethoxymethyl)-1,3-dimethyl-purine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;32 % Polyethylene glycol monomethyl ether 2,000, 0.15 M Potassium bromide, 0.1 M TRIS, pH 9
|
Resolution 1.64 Å R-free 0.231 |
| 6ZZ1 Crystal structure of MLKL executioner domain in complex with a covalent inhibitor Deposited 2020-08-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
2–150(149 aa)
|
Not recorded | QOK 7-(2-methoxyethoxymethyl)-1,3-dimethyl-purine-2,6-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;32 % Polyethylene glycol monomethyl ether 2,000, 0.15 M Potassium bromide, 0.1 M TRIS, pH 9
|
Resolution 1.64 Å R-free 0.231 |
| 7JW7 Structure of monobody 27 human MLKL pseudokinase domain complex Deposited 2020-08-25 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
190–471(282 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;281.15 K;0.2 M magnesium chloride, 20% w/v PEG 3350
|
Resolution 2.63 Å R-free 0.281 |
| 7JXU Structure of monobody 32 human MLKL pseudokinase domain complex Deposited 2020-08-28 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
190–471(282 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;281.15 K;0.1 M Bis-Tris chloride, pH 6.5, 20 % w/v PEG monomethyl ether 5000
|
Resolution 2.44 Å R-free 0.240 |
| 7JXU Structure of monobody 32 human MLKL pseudokinase domain complex Deposited 2020-08-28 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
190–471(282 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;281.15 K;0.1 M Bis-Tris chloride, pH 6.5, 20 % w/v PEG monomethyl ether 5000
|
Resolution 2.44 Å R-free 0.240 |
| 7MON Structure of human RIPK3-MLKL complex Deposited 2021-05-03 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
190–471(282 aa)
|
Not recorded | ZL1 N-[4-({2-[(cyclopropanecarbonyl)amino]pyridin-4-yl}oxy)-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;281.15 K;0.2 M ammonium acetate
30%w/v PEG 4000
0.1 M trisodium citrate-citric acid pH 5.5
|
Resolution 2.23 Å R-free 0.260 |
| 7NM2 Solution structure of MLKL executioner domain in complex with a fragment Deposited 2021-02-23 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
2–154(153 aa)
|
Not recorded | UJ5 2-[(~{S})-methoxy-(4-propan-2-ylphenyl)methyl]-3~{H}-benzimidazole-5-carboxylic acid × 1 |
SOLUTION NMR
NMR measurement conditions
pH 7.1;298 K;Ionic strength (raw mmCIF value) 170;Pressure 1
NMR measurement conditions
pH 7.5;298 K;Ionic strength (raw mmCIF value) 170;Pressure 1
NMR sample composition
430 uM [U-13C; U-15N] MLKL executioner domain, 700 uM Cpd 5, 100% D2O | 100% D2O
NMR sample composition
400 uM [U-13C; U-15N] MLKL executioner domain, 700 uM Cpd 5, 93% H2O/7% D2O | 93% H2O/7% D2O
|
Resolution not provided |
| 7NM4 Solution structure of MLKL executioner domain in complex with a fragment Deposited 2021-02-23 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
2–154(153 aa)
|
Not recorded | UJ8 (~{S})-1~{H}-benzimidazol-2-yl-(4-propan-2-ylphenyl)methanol × 1 |
SOLUTION NMR
NMR measurement conditions
pH 7.1;298 K;Ionic strength (raw mmCIF value) 170;Pressure 1
NMR measurement conditions
pH 7.5;298 K;Ionic strength (raw mmCIF value) 170;Pressure 1
NMR sample composition
385 uM [U-13C; U-15N] MLKL executioner domain, 2000 uM Cpd 3, 100% D2O | 100% D2O
NMR sample composition
315 uM [U-13C; U-15N] MLKL executioner domain, 1600 uM Cpd 3, 93% H2O/7% D2O | 93% H2O/7% D2O
|
Resolution not provided |
| 7NM5 Solution structure of MLKL executioner domain in complex with a fragment Deposited 2021-02-23 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
2–154(153 aa)
|
Not recorded | UJ2 2-[(~{S})-methoxy-(4-phenylphenyl)methyl]-3~{H}-benzimidazole-5-carboxylic acid × 1 |
SOLUTION NMR
NMR measurement conditions
pH 7.5;298 K;Ionic strength (raw mmCIF value) 170;Pressure 1
NMR measurement conditions
pH 7.1;298 K;Ionic strength (raw mmCIF value) 170;Pressure 1
NMR sample composition
400 uM [U-13C; U-15N] MLKL executioner domain, 700 uM Cpd 7, 93% H2O/7% D2O | 93% H2O/7% D2O
NMR sample composition
430 uM [U-13C; U-15N] MLKL executioner domain, 700 uM Cpd 7, 100% D2O | 100% D2O
|
Resolution not provided |
| 8SLZ Crystal structure of phosphorylated (T357/S358) human MLKL pseudokinase domain Deposited 2023-04-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
190–471(282 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293.15 K;0.1 M HEPES pH 7.5, 20%w/v PEG 8000
|
Resolution 2.30 Å R-free 0.234 |
21 other PDB entries and 26 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | MLKL_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A; PDBConstruct 3–283; UniProt 191–471 Author chain B; PDBConstruct 3–283; UniProt 191–471 |